Estados Unidos - inglês - NLM (National Library of Medicine)

nutritional specialties, inc. - alternaria alternata (unii: 52b29rec7h) (alternaria alternata - unii:52b29rec7h), aspergillus niger var. niger (unii: 9ioa40ang6) (aspergillus niger var. niger - unii:9ioa40ang6), candida albicans (unii: 4d7g21hdbc) (candida albicans - unii:4d7g21hdbc), candida parapsilosis (unii: 0kz676d44n) (candida parapsilosis - unii:0kz676d44n), mucor racemosus (unii: 17rh99lq7g) (mucor racemosus - unii:17rh99lq7g), issatchenkia orientalis whole (unii: 138tj2u1sd) (issatchenkia orientalis whole - unii:138tj2u1sd) - aids in temporary relief of rhinitis, itchy eyes, headache, runny nose, fatigue, red or itchy skin† †claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. aids in temporary relief of rhinitis, itchy eyes, headache, runny nose, fatigue, red or itchy skin† †claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Estados Unidos - inglês - NLM (National Library of Medicine)

greer laboratories, inc. - sporisorium cruentum (unii: gqm6lvu5v8) (sporisorium cruentum - unii:gqm6lvu5v8) - allergenic extracts are indicated for the diagnosis and treatment of patients with immediate hypersensitivity allergy to the respective allergens, inhaled, ingested or otherwise introduced into contact with sensitive tissues. the diagnosis of ige‑mediated allergy may be established by the allergy history, clinical evaluation, and skin test reactivity. (4,7,11) immunotherapy with allergenic extracts is indicated when testing and patient history have identified the offending allergens and when it is not possible or practical to avoid these allergens. (12‑14) food extracts have not been proven effective in immunotherapy. the use of allergenic extracts for the above purposes should be made only by physicians with special familiarity and knowledge of allergy. (see dosage and administration) there are no known absolute contraindications to the use of allergenic extracts for immunotherapy. immunotherapy with specific antigens should not be done in those individuals who do not exhibit skin test or clinical sens

Estados Unidos - inglês - NLM (National Library of Medicine)

jubilant hollisterstier llc - yeast (unii: 3ny3sm6b8u) (yeast - unii:3ny3sm6b8u) - yeast 0.1 g in 1 ml - certain diagnostics carry labeling which states allergenic extract for diagnostic use only . data to support the therapeutic use of products labeled with this statement have not been established. 14 in addition to a carefully taken history, the use of glycerin-containing extracts in scratch, prick or puncture testing is an accepted method in the diagnosis of allergic conditions. 1, 2, 3 extracts of all allergens do not produce equivalent results in scratch, prick or puncture tests. the intensity of the skin reactions produced will be determined by two factors: the degree of sensitivity of the patient, and the nature of the allergenic extract applied. scratch, prick or puncture tests are not as sensitive as the intradermal test, but are safer and cause less discomfort. they may, therefore, be the method of choice when a large number of tests are needed, or when testing the pediatric patient. in some cases, where the relatively insensitive scratch, prick or puncture tests are negative or do not confirm the

Estados Unidos - inglês - NLM (National Library of Medicine)

allergy laboratories, inc. - apple (unii: b423vgh5s9) (apple - unii:b423vgh5s9) - apple 1 g in 20 ml - immunotherapy using allergenic extracts is indicated for use in patients with severe allergy symptoms (hay fever, rhinitis, etc.) to pollens, molds, insects, animal danders and various other allergens. immunotherapy is intended for patients whose symptoms are not satisfactorily controlled by avoidance of the offending allergen or by the use of symptomatic medications. treatment uses only those specific allergens that the patient is sensitive to based on diagnostic tests and medical history. it is not intended for treatment of patients who do not manifest immediate hypersensitivity reactions to the allergenic extract following skin testing. there are no known absolute contraindications to diagnostic testing or hyposensitization with allergen immunotherapy.  patients with cardiovascular disease or pulmonary disease such as symptomatic asthma, and/or who are receiving cardiovascular drugs such as beta blockers, may be at higher risk for severe adverse reactions. these patients may also be more refractory to the

Estados Unidos - inglês - NLM (National Library of Medicine)

alk-abello, inc. - quercus rubra pollen (unii: svw19et93c) (quercus rubra pollen - unii:svw19et93c), quercus alba pollen (unii: z4y9zsv4kk) (quercus alba pollen - unii:z4y9zsv4kk), quercus virginiana pollen (unii: 8kdg09a4go) (quercus virginiana pollen - unii:8kdg09a4go) - crab leg, unspecified 0.1 g in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

Estados Unidos - inglês - NLM (National Library of Medicine)

alk-abello, inc. - aspergillus niger var. niger (unii: 9ioa40ang6) (aspergillus niger var. niger - unii:9ioa40ang6), aspergillus repens (unii: sq89e6lome) (aspergillus repens - unii:sq89e6lome), aspergillus flavus var. oryzae (unii: q6z8uk5r3g) (aspergillus flavus var. oryzae - unii:q6z8uk5r3g), aspergillus terreus (unii: qbn8k7055x) (aspergillus terreus - unii:qbn8k7055x) - fraxinus americana pollen 0.05 g in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

apvma permit - metiram(700g/kg) - group m3 fungicide

Estados Unidos - inglês - NLM (National Library of Medicine)

alk-abello, inc. - house dust (unii: eyo007vx98) (house dust - unii:eyo007vx98) - house dust 10000 [pnu] in 1 ml - these products are for diagnostic use only. diagnostic allergenic extracts are indicated for use in skin testing to establish the clinical relevance of specific allergens to which the patient has been exposed. by measuring skin test response, the physician may assess the degree of sensitivity that patients have to the allergens. for extracts standardized in au and bau, see individual directions for use. allergenic extracts for diagnostic use only of coffee, mosquito, cottonseed, and flaxseed have not been shown by adequate data to be safe and effective for therapeutic use. patients on beta blockers can be non-responsive to beta agonists that may be required to reverse a systemic reaction (also, see boxed warning statement and adverse reactions ). the physician should carefully weigh the benefit derived from skin testing vs. the risk to the patient should a systemic reaction arise. patients with unstable asthma or steroid dependent asthmatics and patients with underlying cardiovascular disease are at greater

Estados Unidos - inglês - NLM (National Library of Medicine)

alk-abello, inc. - aspergillus niger var. niger (unii: 9ioa40ang6) (aspergillus niger var. niger - unii:9ioa40ang6), aspergillus repens (unii: sq89e6lome) (aspergillus repens - unii:sq89e6lome), aspergillus flavus var. oryzae (unii: q6z8uk5r3g) (aspergillus flavus var. oryzae - unii:q6z8uk5r3g), aspergillus terreus (unii: qbn8k7055x) (aspergillus terreus - unii:qbn8k7055x) - gibberella zeae 20000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse

Estados Unidos - inglês - NLM (National Library of Medicine)

alk-abello, inc. - solidago canadensis pollen (unii: 644cz16ir5) (solidago canadensis pollen - unii:644cz16ir5) - equus caballus skin 20000 [pnu] in 1 ml - hyposensitization (injection) therapy is a treatment for patients exhibiting allergic reactions to seasonal pollens, dust, molds, animal danders, various other inhalants, and in situations where the offending allergen cannot be avoided. prior to initiation of therapy, the clinical sensitivity should be established by careful evaluation of the patient’s history confirmed by diagnostic skin testing. hyposensitization should not be prescribed for sensitivities to allergens which can easily be avoided. a patient should not be immunized with preparations of allergens to which the patient has not demonstrated symptoms, ige antibodies, positive skin tests, or properly controlled challenge testing. in most cases, immunotherapy is not indicated for those allergens that can be eliminated or minimized by environmental control. patients on beta-blockers are not candidates for immunotherapy, as they can be non-responsive to beta-agonists that may be required to reverse a systemic reaction (also see warnings and adverse